Ipamorelin vs GHRP-2
Both are growth hormone releasing peptides working through the ghrelin receptor, but Ipamorelin is more selective with fewer side effects, while GHRP-2 is more potent but affects cortisol and prolactin.
Last updated: 2026-02-04
Ipamorelin and GHRP-2 are both growth hormone releasing peptides (GHRPs) that stimulate GH secretion through the ghrelin receptor (GHS-R1a). Despite sharing this fundamental mechanism, they offer distinctly different pharmacological profiles that influence their research applications.
GHRP-2 (Growth Hormone Releasing Peptide-2) was one of the earlier GHRPs developed and is known for potent GH release. However, it also stimulates cortisol, prolactin, and appetite to varying degrees.
Ipamorelin was developed later with selectivity as the primary design goal—achieving GH release without significant effects on other hormones. This makes it the "cleanest" GHRP option available.
Understanding these differences is critical for researchers selecting GHRPs for specific protocols. This comparison examines the evidence, mechanisms, and practical considerations for each peptide.
**Important Note:** Neither Ipamorelin nor GHRP-2 is approved for human therapeutic use. Both are prohibited by WADA. This comparison is for educational purposes only.
Quick Comparison Table
| Category | Ipamorelin | GHRP-2 |
|---|---|---|
| Peptide Class | Growth Hormone Releasing Peptide (GHRP) | Growth Hormone Releasing Peptide (GHRP) |
| Amino Acids | 5 amino acids (pentapeptide) | 6 amino acids (hexapeptide) |
| GH Release Potency | Moderate-high | High (among strongest GHRPs) |
| Cortisol Effect | Minimal to none | Moderate increase (10-20%) |
| Prolactin Effect | Minimal to none | Moderate increase |
| Appetite Stimulation | Minimal | Moderate (ghrelin-like) |
| Selectivity | Highly selective for GH | Less selective—affects multiple hormones |
| Half-Life | ~2 hours | ~30 minutes |
| Desensitisation Risk | Low | Moderate |
| Best For | Clean GH release, long-term protocols | Maximum GH output, short-term |
GH Release Mechanisms: Selectivity vs Potency
Ipamorelin
Ipamorelin Mechanism:
Ipamorelin was engineered for selectivity, representing the refinement of GHRP pharmacology:
1. Selective GHS-R1a Activation Primary mechanism: - Binds ghrelin receptor (GHS-R1a) on pituitary somatotrophs - Triggers GH release through calcium signalling - Does NOT significantly activate pathways leading to cortisol/prolactin - Maintains selectivity even at higher doses
2. Clean Hormonal Profile What makes Ipamorelin unique: - No ACTH stimulation → no cortisol elevation - No prolactin increase - Minimal appetite stimulation - No aldosterone or thyroid effects - Truly selective for GH release
3. Pulsatile GH Release Physiological pattern maintenance: - Stimulates distinct GH pulses - Preserves natural secretion rhythm - Does not cause sustained elevation - Better for long-term pituitary function
4. Dose-Response Characteristics Predictable pharmacology: - Linear dose-response curve - Wider therapeutic window - Selectivity maintained across dose range - Saturation around 1 mcg/kg
5. Synergy with GHRH Combination potential: - Excellent synergy with CJC-1295/Mod GRF 1-29 - 5-10x GH release when combined - Preferred GHRP for combination protocols
GHRP-2
GHRP-2 Mechanism:
GHRP-2 prioritises potent GH release over selectivity:
1. Strong GHS-R1a Activation Primary mechanism: - Potent agonist at ghrelin receptor - Among the strongest GHRPs for GH release - Robust activation of calcium signalling - High efficacy at somatotrophs
2. Multiple Hormonal Effects Less selective profile: - Stimulates ACTH → 10-20% cortisol increase - Moderate prolactin elevation possible - Appetite stimulation (ghrelin pathway) - Broader receptor activation
3. Potency Advantage When maximum GH is the goal: - Higher peak GH levels than Ipamorelin - Stronger acute GH pulse - Effective at lower relative doses - Rapid onset of action
4. Shorter Half-Life Pharmacokinetic profile: - ~30 minute half-life - Quicker clearance - May require more frequent dosing - Sharp GH pulse followed by decline
5. Desensitisation Considerations Tolerance development: - Moderate risk of receptor desensitisation - Cycling protocols often recommended - 4-8 weeks on, 2-4 weeks off common - Efficacy may decline with chronic use
Clinical Trial Evidence
Ipamorelin Clinical Studies
Design: Randomised controlled trial
Participants: 114 participants
Ipamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated. There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.
View study — PubMed 25331030Design: Randomised controlled trial
The proposed PK/PD model provides a useful characterization of ipamorelin disposition and GH responses across a range of doses.
View study — PubMed 10496658Design: Review
While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown.
View study — PubMed 41476424Design: Review
In conclusion, peptides represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks. Until longitudinal data clarify their safety and prevalence, peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic.
View study — PubMed 41880199GHRP-2 Clinical Studies
Design: Randomised controlled trial
Growth retardation in yaks was primarily due to somatotropic axis hormones secretion deficiency. Both GHRP-2 and CS administration can accelerate growth performance and GH, IGF-1 secretion in yaks with growth retardation. GHRP-2 enhanced muscle protein deposition mainly by up-regulated the protein synthesis pathways, whereas CS worked mainly by down-regulated the ubiquitin-proteasome pathway.
View study — PubMed 26894743Design: Randomised controlled trial
002). In conclusion, a paradigm examining GHRH-GHRP synergy under a sex steroid clamp reveals highly selective control of basal, pulsatile, and synergistic peptide-driven GH secretion by AVF, E(2), and IGF-I in healthy men.
View study — PubMed 19240251Design: Randomised controlled trial
Participants: 7 participants
Duration: 5 days
Coadministration of GHRP-2, TRH and GnRH reactivated the GH, TSH and LH axes in prolonged critically ill men and evoked beneficial metabolic effects which were absent with GHRP-2 infusion alone and only partially present with GHRP-2 + TRH. These data underline the importance of correcting the multiple hormonal deficits in patients with prolonged critical illness to counteract the hypercatabolic state.
View study — PubMed 12030918Design: Randomised controlled trial
In conclusion, the present results demonstrate that in humans Tyr-Ala-HEX is a GH secretagogue as potent as HEX and GHRP-2, two GHRP-6 superanalogs. Tyr-Ala-HEX also shares with HEX and GHRP-2 the same PRL- ACTH- and cortisol-releasing activity.
View study — PubMed 10195374Benefits Comparison
Ipamorelin Unique Benefits
- Highly selective—GH release without cortisol/prolactin effects
- Minimal appetite stimulation (better for fat loss research)
- Low desensitisation risk—suitable for longer protocols
- Pre-bed dosing ideal (no cortisol to disrupt sleep)
- Excellent for combination with GHRH analogues
- Wider therapeutic window with predictable dosing
- Better tolerated in research settings
Shared Benefits
- Stimulate natural GH release from pituitary
- Work through ghrelin receptor (GHS-R1a)
- Support increased IGF-1 levels
- May enhance recovery and tissue repair
- Synergise with GHRH analogues
- Short half-life allows flexible dosing
- Generally well-tolerated in research
GHRP-2 Unique Benefits
- Higher peak GH levels (among most potent GHRPs)
- Strong acute GH pulse for maximum effect
- Well-characterised pharmacology (extensively studied)
- Effective at relatively low doses
- May support appetite in research requiring weight gain
- Robust GH response even with single doses
Research & Evidence
Ipamorelin Research
Ipamorelin Research Evidence:
Novo Nordisk Development: Ipamorelin underwent significant clinical development: - Phase I/II trials completed - Well-tolerated GH release documented - Selectivity for GH confirmed - Studied for postoperative ileus
Post-Operative Trials: Phase II studies in gut recovery: - 186 patients post-bowel resection - Trend toward faster GI recovery - Excellent safety profile - Development discontinued for commercial reasons
Selectivity Confirmation: Multiple studies validate clean profile: - No significant cortisol elevation - No prolactin increase at therapeutic doses - Appetite effects minimal vs placebo - Thyroid and aldosterone stable
Elderly Population: Studies in older subjects: - Maintained GH-releasing efficacy - Well-tolerated in 65-80 age range - Potential for age-related GH decline
GHRP-2 Research
GHRP-2 Research Evidence:
Early GHRP Development: GHRP-2 was among the first potent GHRPs characterised: - Extensive pharmacological studies - Dose-response well established - Comparison studies vs other GHRPs - Mechanism thoroughly investigated
GH Deficiency Research: Studies in GH-deficient populations: - Robust GH release observed - Diagnostic utility demonstrated - Comparison to GHRH testing - Reliable pituitary stimulation
Anabolic Effects: Body composition research: - Lean mass effects studied - Fat oxidation enhancement - Nitrogen retention improvement - Combined with GHRH analogues
Safety Data: Well-characterised side effect profile: - Cortisol elevation documented - Prolactin effects quantified - Appetite stimulation confirmed - Flushing and water retention noted
Head-to-Head Analysis
Direct Comparison:
Several studies have compared GHRPs head-to-head, allowing evidence-based conclusions:
GH Release: - GHRP-2 produces higher peak GH levels than Ipamorelin - Ipamorelin provides reliable but more moderate GH response - Both effective for significant GH elevation
Hormonal Selectivity: Key differentiator—published data confirms: - Ipamorelin: No significant cortisol or prolactin elevation - GHRP-2: 10-20% cortisol increase, moderate prolactin rise - Ipamorelin: Minimal appetite stimulation - GHRP-2: Noticeable appetite increase (ghrelin pathway)
Practical Implications: - Ipamorelin preferred for clean protocols, pre-bed dosing, fat loss research - GHRP-2 preferred when maximum GH is prioritised over selectivity - Ipamorelin better for long-term, combination protocols - GHRP-2 may require cycling to maintain efficacy
Research Consensus: Ipamorelin has become the preferred GHRP for most research applications due to its selectivity, while GHRP-2 remains relevant when potency is paramount.
Protocol Comparison
Ipamorelin Protocol
Ipamorelin Research Protocols (For Reference Only):
Standard Protocol: - Dose: 200-300 mcg per injection - Frequency: 2-3 times daily - Timing: Morning, post-workout, before bed - Administration: Subcutaneous injection
Saturation Dose: - ~1 mcg/kg body weight per injection - 200-300 mcg covers most individuals - Higher doses show diminishing returns
Key Advantages: - No cortisol effect—ideal for pre-bed dosing - Fasted state enhances GH response - Can be used for extended periods - Low desensitisation risk
Combination Protocol (Most Popular): - Ipamorelin: 200 mcg - Mod GRF 1-29: 100 mcg - Same injection or sequential - 2-3 times daily
⚠️ Not approved for human use. WADA prohibited.
GHRP-2 Protocol
GHRP-2 Research Protocols (For Reference Only):
Standard Protocol: - Dose: 100-300 mcg per injection - Frequency: 2-3 times daily - Timing: Morning, post-workout (pre-bed less ideal due to cortisol) - Administration: Subcutaneous injection
Saturation Dose: - ~1 mcg/kg body weight per injection - Higher doses increase side effects without proportional GH gain
Considerations: - Cortisol elevation may affect sleep if dosed late - Appetite increase may be problematic for fat loss goals - Cycling often recommended (4-8 weeks on, 2-4 weeks off) - More side effects than Ipamorelin
Combination Protocol: - GHRP-2: 100-200 mcg - Mod GRF 1-29 or CJC-1295: 100 mcg - Synergistic GH release - Same considerations apply
⚠️ Not approved for human use. WADA prohibited.
Combined Use
Using Ipamorelin and GHRP-2 Together?
Combining two GHRPs working through the same receptor is unusual and generally not recommended:
Why Combination Is Not Typical: - Both compete for ghrelin receptor (GHS-R1a) - Unlikely to provide additive benefits - May increase side effects without proportional GH gain - One GHRP is typically sufficient
Better Approach: Choose one GHRP and combine with GHRH analogue: - Ipamorelin + Mod GRF 1-29 (most popular, clean profile) - GHRP-2 + Mod GRF 1-29 (higher potency, more side effects)
If Switching Between GHRPs: - No washout period typically needed - Can switch based on goals - Ipamorelin for clean, long-term use - GHRP-2 for short-term maximum output
Safety Profiles
Ipamorelin Safety
Ipamorelin Safety Profile:
Common Effects: - Injection site reactions (mild, transient) - Transient flushing post-injection - Mild water retention - Head rush or light-headedness (uncommon)
Notably Absent (Selectivity Advantage): - No significant cortisol elevation - No prolactin increase - Minimal appetite stimulation - No ACTH effects
This Makes Ipamorelin: - Better tolerated overall - Suitable for pre-bed administration - Lower risk for hormone-sensitive conditions - Preferred for long-term research protocols
Contraindications (Theoretical): - Active malignancy - Pregnancy/breastfeeding - Pituitary abnormalities - Hypersensitivity to peptides
GHRP-2 Safety
GHRP-2 Safety Profile:
Common Effects: - Injection site reactions - Flushing and warmth - Water retention (more pronounced) - Increased appetite - Mild headache
Hormonal Effects: - Cortisol elevation (10-20% increase) - Prolactin increase possible - May affect sleep if dosed late - Potential anxiety from cortisol in sensitive individuals
Considerations: - Less suitable for pre-bed dosing - May counteract fat loss goals (appetite) - Cycling recommended to prevent desensitisation - Monitor for prolactin-related effects
Contraindications (Theoretical): - Active malignancy - Pregnancy/breastfeeding - Conditions worsened by cortisol elevation - Prolactin-sensitive conditions
The Verdict: When to Choose Which?
Choose Ipamorelin When:
- Clean GH release without hormonal disruption is priority
- Pre-bed dosing for sleep/recovery enhancement
- Long-term research protocols without cycling
- Fat loss research where appetite stimulation is undesirable
- Combination with GHRH analogues (standard approach)
- Concern about cortisol elevation or sleep quality
- Better tolerability is prioritised
Choose GHRP-2 When:
- Maximum acute GH release is the primary goal
- Short-term, high-output protocols
- Appetite stimulation is desired (underweight research)
- Willing to cycle and manage side effects
- Potency over selectivity
- Cost considerations (often less expensive)
Consider Combining When:
- Note: Combining two GHRPs is not recommended
- Both work through same receptor (competition, not synergy)
- Instead: Choose one GHRP + add GHRH analogue
- Ipamorelin + Mod GRF 1-29 is gold standard combination
Frequently Asked Questions
Conclusion
Ipamorelin and GHRP-2 represent different design philosophies in GHRP development—selectivity versus potency.
Ipamorelin Advantages: - Highly selective GH release - No cortisol or prolactin elevation - Minimal appetite stimulation - Ideal for pre-bed dosing - Lower desensitisation risk - Better for long-term protocols - Preferred for combination with GHRH
GHRP-2 Advantages: - Higher peak GH output - Potent acute GH release - Well-characterised pharmacology - May support appetite when desired
The Practical Choice: For most research applications, Ipamorelin's selectivity makes it the preferred GHRP. Its clean profile allows flexible dosing, long-term use, and optimal combination with GHRH analogues. GHRP-2 remains relevant when maximum acute GH release is prioritised over tolerability.
For UK Researchers: Neither peptide is approved for therapeutic use. Both are prohibited by WADA in competitive sport. Research use should be under appropriate supervision.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Ipamorelin nor GHRP-2 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.